Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444972 · ClinicalTrials.gov registry record
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
A clinical trial, sponsored by AbbVie.
- Completed
- Registry status
- 998
- Enrollment target
NCT05444972: Completed study, sponsored by AbbVie.
NCT05444972 is a clinical trial that has completed, run by AbbVie. The registered enrollment target is 998 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05444972 has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 998 participants
- Enrollment target
Study Summary
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Primary Outcome
Time from diagnosis of MF to initial treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 998 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2023-11-14 |
What the finished NCT05444972 record still lists
NCT05444972 is an observational study that tracks outcomes without assigning an intervention. The registered 998 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05444972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05444972 about?
NCT05444972 is a clinical study titled "A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review". Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate tre...
What is the current status of trial NCT05444972?
This trial is currently completed. The enrollment target is 998 participants. The study started on 2022-08-23. Estimated completion is 2023-11-14.
Who is sponsoring clinical trial NCT05444972?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
- NCT04703244 · 999 participants
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI